Study HighlightsWhat is the current knowledge on the topic? CP‐I has been identified as an endogenous substrate for hepatic OATP1Bs and MRP2, and accumulates following a single dose of rifampicin, an OATP1Bs/MRP2 inhibitor, thereby presenting as a surrogate probe for DDI assessment.What question did this study address? Does a PBPK model for CP‐I, in which hepatic uptake and efflux processes are incorporated, enable us to describe its pharmacokinetics in the absence and presence of a perpetrator drug such as rifampicin?What does this study add to our knowledge? The presented PBPK modeling approach enables a greater understanding of the mechanisms of CP‐I pharmacokinetics and evaluation of the dose‐dependent inhibitory effects of rifampicin.How might this change drug discovery, development, and/or therapeutics? A useful PBPK model for an important OATP1Bs/MRP2 biomarker (CP‐I) is described. The model can support the translation of the effect of a new chemical entity on CP‐I pharmacokinetics to that on clinically used drugs (e.g., statins). In so doing, the model can complement existing OATP1B‐mediated DDI risk assessment approaches based on agency guidelines.

 {#psp412348-sec-0006}

It has become widely accepted that the combinatorial use of drugs can give rise to clinically relevant drug‐drug interactions (DDIs), especially when the efficacy and safety profile of the victim drug is impacted. Therefore, DDI screening, modeling, and prediction has become standard practice. Such efforts now include the organic anion transporting polypeptides 1B (OATP1B1 and OATP1B3), which are multispecific transporters mediating the sinusoidal uptake of various drugs into hepatocytes. The inhibition of OATP1Bs is an important DDI mechanism that often presents as a significant increase in the systemic exposure of OATP1Bs substrates (e.g., statins, sulfonylureas and meglitinides, and antihepatitis C virus drugs) following the concomitant administration of OATP1B inhibitors, such as cyclosporine A, rifampicin (RIF), and gemfibrozil.[1](#psp412348-bib-0001){ref-type="ref"}, [2](#psp412348-bib-0002){ref-type="ref"}, [3](#psp412348-bib-0003){ref-type="ref"}, [4](#psp412348-bib-0004){ref-type="ref"} Typically, OATP1B *in vitro* inhibition data support DDI risk assessment after following agency guidelines. Such an approach, however, based on a target threshold (e.g., *R* \> 1.1; where *R* = 1 + \[(*f* ~u,p~·*I*)/half‐maximal inhibitory concentration (IC~50~)\]) that if triggered necessitates clinical follow‐up, is known to yield relatively high false‐positive rates.[5](#psp412348-bib-0005){ref-type="ref"} Therefore, various endogenous compounds have been proposed as surrogate probes to facilitate early clinical assessment of pharmacokinetic DDIs, which could reduce the need for unnecessary DDI studies using established probe drugs.[5](#psp412348-bib-0005){ref-type="ref"}

Probe candidates for hepatic OATP1Bs have been reported, such as bilirubin and its glucuronides,[6](#psp412348-bib-0006){ref-type="ref"} bile acids, especially glucuronide and sulfate conjugates,[7](#psp412348-bib-0007){ref-type="ref"}, [8](#psp412348-bib-0008){ref-type="ref"} glucuronide and sulfate conjugates of steroids,[9](#psp412348-bib-0009){ref-type="ref"} fatty acid dicarboxylates,[10](#psp412348-bib-0010){ref-type="ref"} and coproporphyrin I and III (CP‐I and CP‐III). Of these, CP‐I and III, both the byproducts of heme synthesis, can support the evaluation of OATP1B‐mediated DDIs because of their specificity for OATP1B1 and OATP1B3,[11](#psp412348-bib-0011){ref-type="ref"}, [12](#psp412348-bib-0012){ref-type="ref"} sensitivity,[12](#psp412348-bib-0012){ref-type="ref"} and the good association of the area under the plasma concentration‐time curve (AUC) between CP‐I and statins (pitavastatin, atorvastatin, and fluvastatin).[13](#psp412348-bib-0013){ref-type="ref"} Importantly, both plasma CP forms present negligible diurnal variation, which is a desirable characteristic of a biomarker.[12](#psp412348-bib-0012){ref-type="ref"}, [13](#psp412348-bib-0013){ref-type="ref"}

Mechanistic physiologically based pharmacokinetic (PBPK) modeling has increasingly been used as a tool to predict DDIs in recent years by combining the PBPK models of both victim and perpetrator. In this study, we aimed to establish a PBPK model for CP‐I in which hepatic uptake and efflux processes are considered. Followed by hepatic uptake, CP‐I undergoes biliary excretion[14](#psp412348-bib-0014){ref-type="ref"} via multidrug resistance‐associated protein 2 (MRP2).[15](#psp412348-bib-0015){ref-type="ref"} Clinical data, obtained with the positron emission tomography probe \[^11^C\]‐TIC‐Me, has shown that MRP2‐mediated biliary excretion[16](#psp412348-bib-0016){ref-type="ref"} can be significantly inhibited by RIF at a clinically relevant dose (600 mg). Such data suggest the DDI potential of RIF against MRP2,[17](#psp412348-bib-0017){ref-type="ref"} but *in vitro* inhibition data can be problematic because of the high variability in the reported values of *in vitro* inhibition constants (*K* ~i~) for MRP2 (7.9--83 μM, as listed in the University of Washington Metabolism and Transport Drug Interaction Database). Overall, it was considered important to account for the involvement of both hepatic OATP1Bs and MRP2 in the interaction between CP‐I and RIF. CP‐I is also excreted into the urine, and its renal clearance is not significantly altered after the administration of RIF (600 mg).[12](#psp412348-bib-0012){ref-type="ref"}

We previously presented a stepwise protocol to analyze multiple clinical cases of DDI involving drug transporters using a standardized PBPK model structure and unified model parameters for each victim or perpetrator drug.[18](#psp412348-bib-0018){ref-type="ref"} Using this standardized protocol and a previously established model for RIF,[19](#psp412348-bib-0019){ref-type="ref"} we constructed a PBPK model for CP‐I and optimized parameters, including *K* ~i~ for OATP1Bs, which could explain our clinical data showing a dose response with oral RIF at 300 and 600 mg.[13](#psp412348-bib-0013){ref-type="ref"} Subsequently, we evaluated the predictability of the DDIs between statins and RIF in the same clinical dataset,[13](#psp412348-bib-0013){ref-type="ref"} taking into account the difference between the *in vitro K* ~i~ of RIF for statins and CP‐I. Accounting for intersubstrate differences in *K* ~i~ is consistent with the recent report of Barnett *et al*.,[20](#psp412348-bib-0020){ref-type="ref"} who considered the IC~50~ values of RIF for both CP‐I and rosuvastatin *in vitro* and conducted mixed model analysis of clinical interaction data. Such considerations enhance the value of a PBPK model used to translate CP‐I interaction data to other OATP1B substrates.

Methods {#psp412348-sec-0007}
=======

Overview of PBPK modeling and simulation strategy {#psp412348-sec-0008}
-------------------------------------------------

We previously reported a framework for constructing PBPK models.[18](#psp412348-bib-0018){ref-type="ref"} A PBPK model for CP‐I was constructed by introducing a parameter for CP‐I biosynthesis (*v* ~syn~) into our previously proposed PBPK model (**Supplementary Text** [S1](#psp412348-sup-0008){ref-type="supplementary-material"}). The *v* ~syn~ was incorporated in the liver compartment; CP‐I and CP‐III are spontaneously generated from coproporphyrinogen I and III, which are synthesized from uroporphyrinogen I and III by uroporphyrinogen decarboxylase expressed in both liver and erythrocytes. In patients of porphyria cutanea tarda caused by a deficient hepatic activity of uroporphyrinogen decarboxylase due to hepatitis,[21](#psp412348-bib-0021){ref-type="ref"} the urinary ratio of CPs to uroporphyrins (spontaneously generated from uroporphyrinogens) was decreased to 0.28, whereas the ratio was 4.2 in healthy volunteers,[22](#psp412348-bib-0022){ref-type="ref"} suggesting \> 90% of CPs in humans in normal condition is synthesized in the liver. Thus, we regarded the liver as the major organ for CP‐I biosynthesis. The enterohepatic circulation (EHC) of CP‐I was incorporated in the model according to a previous report of kinetic model analyses using the plasma concentration data and urinary and fecal excretion data of ^14^C‐labeled CP‐I and CP‐III.[23](#psp412348-bib-0023){ref-type="ref"} Using the PBPK model and parameters for RIF reported by Asaumi *et al*.,[19](#psp412348-bib-0019){ref-type="ref"} RIF‐mediated inhibition of hepatic OATP1B and MRP2 was incorporated. Differential equations and other equation settings describing the PBPK model are presented in **Supplementary Text** [S1](#psp412348-sup-0008){ref-type="supplementary-material"}. Finally, (i) simulation of blood concentration‐time profiles of CP‐I in the absence and presence of RIF, (ii) sensitivity analyses to examine the impact of change in each parameter on the simulation outcome, and (iii) parameter optimization by nonlinear least‐squares fitting were performed.

Simulation designs for our clinical study[13](#psp412348-bib-0013){ref-type="ref"} (volunteers, drug administration, time course, and sampling) and model parameter settings are described in **Supplementary Text** [S1](#psp412348-sup-0008){ref-type="supplementary-material"}. Details for uptake and efflux experiments using plated human hepatocytes (**Figure** [S1](#psp412348-sup-0001){ref-type="supplementary-material"}) for the determination of hepatic membrane permeation parameters for CP‐I are also described in **Supplementary Text** [S1](#psp412348-sup-0008){ref-type="supplementary-material"}.

Software {#psp412348-sec-0009}
--------

The nonlinear least‐squares fitting software, Napp version 2.31,[24](#psp412348-bib-0024){ref-type="ref"} was used in all the optimization and simulation processes applied in the present study. The weight for the nonlinear least‐squares calculation was set as the square root of the original value. The weighted sum of squares (WSS) and the Akaike\'s information criteria (AIC) shown in Eqs. [(1)](#psp412348-disp-0001){ref-type="disp-formula"} and [(2)](#psp412348-disp-0002){ref-type="disp-formula"}, respectively, were used to evaluate the fitting results. $$\text{WSS} = \sum\limits_{i = 1}^{n}\frac{{(y_{i} - y_{i}^{\prime})}^{2}}{y_{i}},$$

*y* ~*i*~: *i*th observed value, $y_{i}^{\prime}$: *i*th predicted value. $$\text{AIC} = n \times \text{ln}\,\text{WSS} + 2m.$$

Model predictability {#psp412348-sec-0010}
--------------------

To quantitatively evaluate model predictability for blood concentration‐time profiles, AUC ratio, and maximum blood concentration (C~max~) ratio, commonly used accuracy test criteria, the average fold errors (AFEs), were calculated, as shown in Eq. [(3)](#psp412348-disp-0003){ref-type="disp-formula"}: $$\text{AFE} = 10^{\frac{\sum_{i = 1}^{n}{|{\log\frac{Predicted}{Observed}}|}}{n}},$$ where *n* is the number of observations.

Results {#psp412348-sec-0011}
=======

Simulation of blood and liver concentration‐time profiles of RIF using the reported PBPK model {#psp412348-sec-0012}
----------------------------------------------------------------------------------------------

As shown in **Figure** [1](#psp412348-fig-0001){ref-type="fig"}, the observed blood concentration‐time profiles of RIF administered orally at 300 and 600 mg[13](#psp412348-bib-0013){ref-type="ref"} were reproduced by the simulation with the comprehensive PBPK model and parameters reported previously.[19](#psp412348-bib-0019){ref-type="ref"} The unbound blood concentration of RIF reached maximum values of 0.43 and 0.94 μM with 300 mg (**Figure** [1](#psp412348-fig-0001){ref-type="fig"} **a**) and 600 mg (**Figure** [1](#psp412348-fig-0001){ref-type="fig"} **b**) administration, respectively. The predicted intrahepatic unbound concentration reached maximum values of 1.0 and 1.5 μM following 300 and 600 mg administration, respectively.

![Simulation of the blood and liver concentration‐time profiles of rifampicin (RIF). The circles represent the observed blood concentrations of RIF administered at (**a**) 300 mg and (**b**) 600 mg, orally (mean ± SD,*n* = 8).[13](#psp412348-bib-0013){ref-type="ref"} The solid line represents a simulated blood concentration‐time profile using the physiologically based pharmacokinetic model and parameters reported previously.[19](#psp412348-bib-0019){ref-type="ref"} The dotted line represents a simulated blood unbound concentration‐time profile. The broken line represents a simulated intrahepatic unbound concentration‐time profile (the first hepatocyte compartment shown in **Supplementary Text** [S1](#psp412348-sup-0008){ref-type="supplementary-material"}).](PSP4-7-739-g001){#psp412348-fig-0001}

Setting of *in vivo* inhibition constants for OATP1Bs and MRP2 by RIF {#psp412348-sec-0013}
---------------------------------------------------------------------

To simulate the dynamic change in the blood concentration of CP‐I caused by RIF, the *in vivo K* ~i,u,OATP1Bs~ (0.23 μM)[18](#psp412348-bib-0018){ref-type="ref"} was set initially. Our *in vitro* experiments using OATP1B‐expressing cells (**Figure** [S2](#psp412348-sup-0002){ref-type="supplementary-material"}) suggested that the calculated *K* ~i~ for OATP1B1 (0.78 μM) and that for OATP1B3 (0.18 μM) using CP‐I as a substrate tends to be lower than those using statins as substrates (1.1--2.8 μM for OATP1B1, 0.30--0.86 μM for OATP1B3; **Table** [S2](#psp412348-sup-0007){ref-type="supplementary-material"}). Thus, we assumed some intersubstrate differences in the inhibitory characteristics by RIF, as reported previously.[25](#psp412348-bib-0025){ref-type="ref"} As part of the PBPK‐enabled modeling exercise, we considered a range of *in vivo K* ~i,u,OATP1Bs~ values (between 0.33‐fold and 3‐fold of the initial value) to support parameter sensitivity (**Figure** [S3](#psp412348-sup-0003){ref-type="supplementary-material"}) and optimization by fitting (**Figure** [2](#psp412348-fig-0002){ref-type="fig"}). In addition, the *in vivo K* ~i,u,MRP2~ (0.87 μM), calculated based on the change in the biliary clearance of \[^11^C\]‐TIC‐Me,[17](#psp412348-bib-0017){ref-type="ref"} was used (see details in **Supplementary Text** [S1](#psp412348-sup-0008){ref-type="supplementary-material"}).

![Simultaneously fitted blood concentration‐time profiles of coproporphyrin (CP)‐I in the absence and presence of rifampicin (RIF) after parameter optimization using the physiologically based pharmacokinetic (PBPK) model incorporating the inhibition of organic anion‐transporting polypeptide (OATP)1Bs and multidrug resistance‐associated protein 2 (MRP)2. The blue (control), green (300 mg RIF, orally), and red (600 mg RIF, orally) circles represent the observed blood concentrations of CP‐I (mean ± SD,*n* = 8).[13](#psp412348-bib-0013){ref-type="ref"} The lines represent simultaneously fitted blood concentration--time profiles after optimization of parameters in the PBPK model, in which the inhibition of hepatic OATP1Bs and MRP2 by RIF are incorporated. The fixed and optimized parameters are shown in **Tables** [2](#psp412348-tbl-0002){ref-type="table"} and [S1](#psp412348-sup-0006){ref-type="supplementary-material"} **A,B**. The β values are set at 0.8 (**a**), 0.5 (**b**), and 0.2 (**c**).](PSP4-7-739-g002){#psp412348-fig-0002}

Sensitivity analyses of model parameters to demonstrate the effects on the blood concentration‐time profiles of CP‐I {#psp412348-sec-0014}
--------------------------------------------------------------------------------------------------------------------

The blood concentration‐time profile of CP‐I following RIF administration was simulated (**Figure** [S3](#psp412348-sup-0003){ref-type="supplementary-material"}) using the constructed PBPK model and parameters shown in **Table** [1](#psp412348-tbl-0001){ref-type="table"} and **Table** [S1](#psp412348-sup-0006){ref-type="supplementary-material"}. Sensitivity analyses of the hepatic overall intrinsic clearance, CL~int,all~ (and correspondingly altered *v* ~syn~ according to the theoretical equation shown in **Supplementary Text** [S1](#psp412348-sup-0008){ref-type="supplementary-material"}) showed that these parameters could change the turnover of CP‐I and the magnitude of the interaction with RIF. As the CL~int,all~ and *v* ~syn~ are increased, the RIF‐mediated interaction is increased regardless of the different preset β values of 0.8 (**Figure** [S3](#psp412348-sup-0003){ref-type="supplementary-material"} **a**), 0.5 (**Figure** [S3](#psp412348-sup-0003){ref-type="supplementary-material"} **b**), and 0.2 (**Figure** [S3](#psp412348-sup-0003){ref-type="supplementary-material"} **c**). In addition, our sensitivity analyses also showed that the OATP1B inhibitor potency, reflected by *K* ~i,u,OATP1Bs~ (**Figure** [S3](#psp412348-sup-0003){ref-type="supplementary-material"} **d--f**), was a determinant of the interaction between RIF and CP‐I.

###### 

Parameters used in the simulation of the blood concentration‐time profiles of CP‐I in the absence and presence of RIF (**Figure** [S3](#psp412348-sup-0003){ref-type="supplementary-material"})

  ID   CL~int,all~ [a](#psp412348-note-0003){ref-type="fn"}   *v* ~syn~ [b](#psp412348-note-0003){ref-type="fn"}   β[c](#psp412348-note-0003){ref-type="fn"}   *R* ~dif~ [d](#psp412348-note-0003){ref-type="fn"}   γ[d](#psp412348-note-0003){ref-type="fn"}   *f* ~bile~ [e](#psp412348-note-0003){ref-type="fn"}   *k* ~transit~ [e](#psp412348-note-0003){ref-type="fn"}   *k* ~a~ [e](#psp412348-note-0003){ref-type="fn"}   *F* ~a~ *F* ~g~ [e](#psp412348-note-0003){ref-type="fn"}   *K* ~i,u,OATP1Bs~ [f](#psp412348-note-0003){ref-type="fn"}   *K* ~i,u,MRP2~ [g](#psp412348-note-0003){ref-type="fn"}
  ---- ------------------------------------------------------ ---------------------------------------------------- ------------------------------------------- ---------------------------------------------------- ------------------------------------------- ----------------------------------------------------- -------------------------------------------------------- -------------------------------------------------- ---------------------------------------------------------- ------------------------------------------------------------ ---------------------------------------------------------
  A    33.3                                                   0.153                                                0.8                                         0.035                                                0.020                                       0.84                                                  5.2                                                      3.0                                                0.66                                                       0.23                                                         0.87
  B    33.3                                                   0.125                                                0.5                                         0.035                                                0.020                                       0.84                                                  5.2                                                      3.0                                                0.66                                                       0.23                                                         0.87
  C    33.3                                                   0.105                                                0.2                                         0.035                                                0.020                                       0.84                                                  5.2                                                      3.0                                                0.66                                                       0.23                                                         0.87

$\beta = \text{CL}_{{int},{all}}/{(\text{PS}_{{act},\inf} + \text{PS}_{{dif},\inf})},R_{dif} = \text{PS}_{{dif},\inf}/\text{PS}_{{{act},\inf,}\gamma} = \text{PS}_{{dif},\inf}/\text{PS}_{{dif},{eff}},f_{bile} = \text{CL}_{{int},{bile}}/{(\text{CL}_{{int},{bile}} + \text{CL}_{{int},{met}})}.$

CP‐I, coproporphyrin; RIF, rifampicin.

^a^Calculated from the reported CL~int,all~ of 14C‐CP‐III administered intravenously to humans.[23](#psp412348-bib-0023){ref-type="ref"} ^b^Calculated using the parameters including CL~int,all~ and *F* ~a~ *F* ~g~ according to Eqs. S7--S10. See details in [METHODS](#psp412348-sec-0007){ref-type="sec"}. ^c^Fixed to three different values indicating different conditions of the major rate‐determining processes in the hepatic intrinsic clearance. ^d^Calculated according to the *in vitro* data using plated human hepatocytes. See details in [METHODS](#psp412348-sec-0007){ref-type="sec"}. ^e^Derived from the previous multicompartment analyses using 14C‐labeled coproporphyrins in humans.[23](#psp412348-bib-0023){ref-type="ref"} ^f^The *in vivo K* ~i,u,OATP1Bs~ estimated from physiologically based pharmacokinetic analyses of the drug‐drug interaction between pitavastatin and rifampicin.[18](#psp412348-bib-0018){ref-type="ref"} ^g^Calculated based on the change in the *in vivo* biliary excretion clearance reported in the previous clinical study using a positron emission tomography probe (11C‐TIC‐Me).[17](#psp412348-bib-0017){ref-type="ref"}

John Wiley & Sons, Ltd

To evaluate the effects of *K* ~i,u,MRP2~ and other parameters relating to EHC (*F* ~a~ *F* ~g~, *k* ~a~, and *k* ~transit~), whose initial values were derived from the previous report,[23](#psp412348-bib-0023){ref-type="ref"} further sensitivity analyses were performed (**Figure** [S3](#psp412348-sup-0003){ref-type="supplementary-material"} **g--l**). The *K* ~i,u,MRP2~ slightly affected the CP‐I blood concentration when the β value was set at 0.5 and 0.2 (**Figure** [S3](#psp412348-sup-0003){ref-type="supplementary-material"} **h,i**). As the *F* ~a~ *F* ~g~ is decreased, RIF‐mediated interaction is increased (**Figure** [S3](#psp412348-sup-0003){ref-type="supplementary-material"} **j--l**). Little change in the magnitude of the interaction was observed in sensitivity analyses of *k* ~a~ and *k* ~transit~ (data not shown).

Previous evidences suggested that \> 90% of CPs in humans in normal condition is synthesized in the liver.[22](#psp412348-bib-0022){ref-type="ref"} We performed sensitivity analyses setting the fraction of CP‐I biosynthesis in the liver (*f* ~syn~) as 1, 0.9, and 0.8 (**Figure** [S3](#psp412348-sup-0003){ref-type="supplementary-material"} **m--o**). Little change in the magnitude of the interaction was observed with these different *f* ~syn~. Thus, we used *f* ~syn~ = 1 in the following analyses.

Optimization of model parameters by fitting of the blood concentration‐time profiles of CP‐I {#psp412348-sec-0015}
--------------------------------------------------------------------------------------------

Because CL~int,all~ (*v* ~syn~), *K* ~i,u,OATP1Bs~, and *F* ~a~ *F* ~g~ markedly affected the magnitude of interaction between CP‐I and RIF (**Figure** [S3](#psp412348-sup-0003){ref-type="supplementary-material"} **a--f,j--l**), these parameters were optimized by nonlinear least‐square fitting to the CP‐I blood concentration‐time profiles in the absence and presence of RIF[13](#psp412348-bib-0013){ref-type="ref"} simultaneously. These parameters were moved freely between 0.33‐fold and 3‐fold in the initial values described in **Table** [1](#psp412348-tbl-0001){ref-type="table"}. We could obtain parameter sets that can explain the observed data (**Figure** [2](#psp412348-fig-0002){ref-type="fig"} **a--c**). The optimized CL~int,all~, *v* ~syn~, and *F* ~a~ *F* ~g~ were 35.1--43.1 l/h/kg, 0.212--0.442 nmol/h/kg, and 0.256--0.318, respectively, depending on the setting of β values (**Table** [2](#psp412348-tbl-0002){ref-type="table"}). The optimized values of *K* ~i,u,OATP1Bs~ ranged between 0.0824 and 0.106 μM, which were 0.36‐fold to 0.46‐fold of the initial value (0.23 μM).

###### 

Parameters fixed and optimized in the fitting of the blood concentration‐time profiles of CP‐I in the absence and presence of RIF (**Figure** [2](#psp412348-fig-0002){ref-type="fig"})

  ID   CL~int,all~   *v* ~syn~ [a](#psp412348-note-0003){ref-type="fn"}   β     *R* ~dif~   γ       *f* ~bile~   *k* ~transit~   *k* ~a~   *F* ~a~ *F* ~g~   *K* ~i,u,OATP1Bs~   *K* ~i,u,MRP2~          
  ---- ------------- ---------------------------------------------------- ----- ----------- ------- ------------ --------------- --------- ----------------- ------------------- ---------------- ------ ------
  A    35.1 ± 2.7    0.442 (0.345--0.567)                                 0.8   0.035       0.020   0.84         5.2             3.0       0.256 ± 0.067     0.0824 ± 0.0105     0.87             1.73   19.1
  B    38.3 ± 2.4    0.264 (0.219--0.315)                                 0.5   0.035       0.020   0.84         5.2             3.0       0.309 ± 0.079     0.0965 ± 0.0123     0.87             1.75   19.5
  C    43.1 ± 2.3    0.212 (0.182--0.245)                                 0.2   0.035       0.020   0.84         5.2             3.0       0.318 ± 0.087     0.106 ± 0.013       0.87             1.81   20.2

$\beta = \text{CL}_{{int},{all}}/{(\text{PS}_{{act},\inf} + \text{PS}_{{dif},\inf})},R_{dif} = PS_{{dif},\inf}/PS_{{{act},\inf,}\gamma} = \text{PS}_{{dif},\inf}/\text{PS}_{{dif},{eff}},f_{bile} = \text{CL}_{{int},{bile}}/{(\text{CL}_{{int},{bile}} + \text{CL}_{{int},{met}})}$

AIC, Akaike information criterion; CP‐I, coproporphyrin; RIF, rifampicin.

Calculated using the parameters including CL~int,all~ and *F* ~a~ *F* ~g~ according to Eqs. S7--S10. In the parentheses, the minimum and maximum values calculated using SDs of CL~int,all~ and *F* ~a~ *F* ~g~ are described.
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Simulation of blood concentration‐time profiles of CP‐I using its optimized parameters and PBPK model incorporating the inhibition of OATP1Bs alone {#psp412348-sec-0016}
---------------------------------------------------------------------------------------------------------------------------------------------------

To compare the contribution of OATP1Bs and MRP2 to the magnitude of the CP‐I‐RIF interaction, a simulation was performed using a PBPK model for CP‐I, in which only the inhibition of hepatic OATP1Bs by RIF was incorporated. Using the parameters described in **Table** [2](#psp412348-tbl-0002){ref-type="table"}, with exclusion of *K* ~i,u,MRP2~, the simulated CP‐I blood concentrations (**Figure** [S4](#psp412348-sup-0004){ref-type="supplementary-material"} **a--c**) were lower than those using the original PBPK model incorporating dual (OATP1Bs/MRP2) inhibition (**Figure** [2](#psp412348-fig-0002){ref-type="fig"} **a--c**). Such a model‐dependent difference was more significant when the β value was set lower.

The observed and the simulated AUC~0--24\ h~ and C~max~ of CP‐I in the presence of RIF are summarized in **Table** [3](#psp412348-tbl-0003){ref-type="table"}. The simulated AUC and C~max~ using the PBPK model with dual OATP1Bs/MRP2‐inhibition were around 96% and 102--108% of the observed values, respectively. In comparison, the simulated AUC and C~max~ using the PBPK model with OATP1B inhibition only was 75--85% and 79--89% vs. the observed values, respectively.

###### 

The blood AUC and C~max~ of CP‐I estimated by PBPK modeling compared to the observation

                                                                                                                  AUC~0--24h~ (nM h)   C~max~ (nM)                 
  ------------------------------------------------------------------------------------------------- ------------- -------------------- ------------- ------------- -------------
  Observation[a](#psp412348-note-0004){ref-type="fn"}                                               --            23.9 ± 4.8           36.3 ± 6.7    1.61 ± 0.38   2.30 ± 0.35
  Inhibition of OATP1Bs and MRP2 (**Figure** [2](#psp412348-fig-0002){ref-type="fig"})              0.8           23.0 (96.2)          34.8 (95.9)   1.73 (108)    2.35 (102)
  0.5                                                                                               22.9 (95.8)   34.8 (95.9)          1.73 (108)    2.36 (103)    
  0.2                                                                                               22.9 (95.8)   34.7 (95.6)          1.74 (108)    2.36 (103)    
  Inhibition of OATP1Bs (**Figure** [S4](#psp412348-sup-0004){ref-type="supplementary-material"})   0.8           20.3 (84.9)          29.0 (79.9)   1.43 (88.8)   1.87 (81.3)
  0.5                                                                                               19.3 (80.8)   27.5 (75.8)          1.35 (83.9)   1.79 (77.8)   
  0.2                                                                                               19.0 (79.5)   27.3 (75.2)          1.35 (83.9)   1.80 (78.3)   

In the parentheses, the estimation/observation ratios (%) are shown.

AUC, area under the plasma concentration‐time curve; C~max~, peak plasma concentration; CP‐I, coproporphyrin I; MRP2, multidrug resistance‐associated protein 2; OATP, organic anion‐transporting polypeptide; PBPK, physiologically based pharmacokinetic; RIF, rifampicin.

Data from the previous study.[13](#psp412348-bib-0013){ref-type="ref"}
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Prediction of the effect of RIF on blood concentration‐time profiles of statins using their PBPK models and parameters including substrate‐dependent *K* ~i,u,OATP1Bs~ {#psp412348-sec-0017}
----------------------------------------------------------------------------------------------------------------------------------------------------------------------

We evaluated the predictability of DDIs between four statins and RIF using our clinical data,[13](#psp412348-bib-0013){ref-type="ref"} as well as the *K* ~i,u,OATP1Bs~ for CP‐I optimized by PBPK modeling (**Table** [2](#psp412348-tbl-0002){ref-type="table"}) and the ratio of *in vitro K* ~i~ for each statin to CP‐I (**Table** [S2](#psp412348-sup-0007){ref-type="supplementary-material"}). Previously reported PBPK models for pitavastatin, fluvastatin,[18](#psp412348-bib-0018){ref-type="ref"} rosuvastatin,[26](#psp412348-bib-0026){ref-type="ref"} and a newly constructed PBPK model for atorvastatin, whose structure is the same as pitavastatin and fluvastatin, leveraged their basic physiological and pharmacokinetic parameters (**Table** [S1](#psp412348-sup-0006){ref-type="supplementary-material"} **A,C**). After obtaining some parameters by fitting to the control data alone (**Table** [S1](#psp412348-sup-0006){ref-type="supplementary-material"} **D**), the blood concentration‐time profile of each statin in the presence of RIF was simulated (**Figure** [3](#psp412348-fig-0003){ref-type="fig"} **a--d**) using substrate‐dependent *K* ~i,u,OATP1Bs~, shown in **Table** [S1](#psp412348-sup-0006){ref-type="supplementary-material"} **D**, calculated by multiplying the *K* ~i,u,OATP1Bs~ for CP‐I by the ratio of *in vitro K* ~i~ for OATP1B1 (statin/CP‐I). AFEs for concentration‐time predictions in the presence of 300 and 600 mg RIF were calculated to be 1.71/1.97, 1.87/2.42, 1.50/1.56, and 1.43/1.73 for pitavastatin, rosuvastatin, atorvastatin, and fluvastatin, respectively. The predicted AUC and C~max~ of statins were well‐correlated with their observed AUC and C~max~ (**Figure** [3](#psp412348-fig-0003){ref-type="fig"} **e,f**).

![Prediction of the effect of rifampicin (RIF) on blood concentration‐time profiles of statins using their physiologically based pharmacokinetic (PBPK) models and parameters, including substrate‐dependent *K* ~i,u,OATP1Bs~. (**a--d**) The blue (control), green (300 mg RIF, orally), and red (600 mg RIF, orally) circles represent the observed blood concentrations of statins (mean ± SD,*n* = 8).[13](#psp412348-bib-0013){ref-type="ref"} The blue solid lines (control) represent fitted blood concentration‐time profiles of statins after optimization of parameters in their PBPK models. The green and red broken lines (+RIF) represent predicted blood concentration‐time profiles of statins. (**a**) pitavastatin, (**b**) rosuvastatin, (**c**) atorvastatin, and (**d**) fluvastatin. The used parameters, including substrate‐dependent *K* ~i,u,OATP1Bs~ values are shown in **Table** [S1](#psp412348-sup-0006){ref-type="supplementary-material"} **A,C,D**. (**e, f**) Comparison of the predicted and observed area under the plasma concentration‐time curve (AUC) (**e**) and peak plasma concentration (C~max~) (**f**) of statins in the absence and presence of RIF. The AUC and C~max~ of coproporphyrin (CP)‐I are also shown. Dashed and dotted lines denote unity and threefold boundaries, respectively.](PSP4-7-739-g003){#psp412348-fig-0003}

On the other hand, when the prediction was performed using the *in vivo K* ~i,u,OATP1Bs~ for CP‐I (0.1 μM) without any correction (**Figure** [S5](#psp412348-sup-0005){ref-type="supplementary-material"} **a--d**), AFEs were calculated to be 2.11/2.54, 1.92/2.53, 1.61/2.34, and 2.63/2.98 for pitavastatin, rosuvastatin, atorvastatin, and fluvastatin with 300 and 600 mg RIF, respectively. Therefore, the inhibitory effect of RIF was overestimated, except for rosuvastatin whose *in vitro* RIF *K* ~i~ was not so different from CP‐I. The predicted (without correcting *K* ~i,u,OATP1Bs~) vs. observed AUC and C~max~ are shown in **Figure** [S5](#psp412348-sup-0005){ref-type="supplementary-material"} **e,f**.

Finally, the AUC ratio and C~max~ ratio were calculated, as shown in **Figure** [S5](#psp412348-sup-0005){ref-type="supplementary-material"} **g--**j. In this instance, with correction of the *in vivo K* ~i~ based on differences of *in vitro K* ~i~, the AFE for predicted vs. observed AUC ratio was 1.20, and that for the C~max~ ratio was 1.36 (**Figure** [S5](#psp412348-sup-0005){ref-type="supplementary-material"} **g,h**). Without correction of the *in vivo K* ~i~ based on differences of *in vitro K* ~i~, AFE values for the AUC ratio and C~max~ ratio were higher (1.74 and 1.39, respectively; **Figure** [S5](#psp412348-sup-0005){ref-type="supplementary-material"} **i,j**).

Discussion {#psp412348-sec-0018}
==========

In this study, a PBPK model for CP‐I was constructed to provide mechanistic insight regarding the dose‐dependent inhibition of OATP1B and MRP2 by RIF. Sensitivity analyses demonstrated that model parameters including the *in vivo K* ~i,u,OATP1Bs~, *v* ~syn~, and CL~int,all~, could affect CP‐I blood concentration‐time profiles following RIF. After optimization of these parameters by nonlinear least‐squares fitting, blood concentration‐time profiles of statins affected by RIF were well‐predicted using substrate‐dependent *K* ~i~ values.

The initial value in our present analyses was based on the *in vivo K* ~i,u,OATP1Bs~ values of RIF, which were estimated to be 0.23 μM (vs. pitavastatin) and 0.19 μM (vs. pravastatin) in our previous PBPK‐DDI analyses.[18](#psp412348-bib-0018){ref-type="ref"} Parameter optimization yielded 0.37‐fold to 0.48‐fold of the initial *K* ~i,u,OATP1Bs~ (0.082--0.11 μM in **Table** [2](#psp412348-tbl-0002){ref-type="table"}) to explain the CP‐I blood concentration‐time profiles with RIF (**Figure** [2](#psp412348-fig-0002){ref-type="fig"}). Some substrate‐dependent differences in the sensitivity to OATP1B inhibitors *in vitro*, including RIF, have been reported.[25](#psp412348-bib-0025){ref-type="ref"} In order to support the intersubstrate difference suggested by the model‐based analysis in this study, we compared the inhibition profiles of RIF between CP‐I and the statins, by performing uptake experiments using OATP1B1/OATP1B3‐expressing HEK293 cells (**Figure** [S2](#psp412348-sup-0002){ref-type="supplementary-material"}). The calculated *K* ~i~ values for OATP1B1 and OATP1B3 were 1.5‐fold to 3.6‐fold and 1.6‐fold to 4.8‐fold lower using CP‐I as a substrate than using statins (**Table** [S2](#psp412348-sup-0007){ref-type="supplementary-material"}), which might support the lower estimated *in vivo K* ~i,u,OATP1Bs~ for CP‐I (**Table** [2](#psp412348-tbl-0002){ref-type="table"}) than for statins.[18](#psp412348-bib-0018){ref-type="ref"}

By comparing the simulation results using the model incorporating dual OATP1B/MRP2 inhibition (**Figure** [2](#psp412348-fig-0002){ref-type="fig"}), to that incorporating OATP1B inhibition only (**Figure** [S4](#psp412348-sup-0004){ref-type="supplementary-material"}), 75--85% of the observed AUC and 78--89% of the observed C~max~ were explained by inhibition of OATP1Bs (**Table** [3](#psp412348-tbl-0003){ref-type="table"}), and the remaining by inhibition of MRP2. Thus, OATP1Bs had a major contribution to the magnitude of the CP‐I‐RIF interaction; however, the magnitude suggests that the influence of MRP2 inhibition on CP‐I pharmacokinetics should not be ignored during the assessment of DDIs.

Using the first model with an initial parameter setting (**Figure** [S3](#psp412348-sup-0003){ref-type="supplementary-material"}), sensitivity analysis of *K* ~i,u,MRP2~ from 0.33 to 3‐fold of the initial value affected blood concentrations in the presence of RIF (especially when β = 0.8) less significantly than *K* ~i,u,OATP1Bs~. Actually, the contribution of RIF‐mediated inhibition of MRP2 was estimated to be \~10% of the AUC increase at most (β = 0.5 and 0.2). The reduced impact of *K* ~i,u,MRP2~ on CP‐I blood concentrations is expected because of (i) increased sinusoidal efflux of CP‐I is offset by (ii) the decreased EHC (with *F* ~a~ *F* ~g~ of 0.66) of CP‐I, both due to the inhibition of MRP2‐mediated biliary excretion. On the other hand, the effect of MRP2‐inhibition was more clearly observed when using the final model with an optimized parameter setting (**Figure** [2](#psp412348-fig-0002){ref-type="fig"}), because (I) a larger *v* ~syn~ setting led to the more significant effect of RIF, and (II) a smaller *F* ~a~ *F* ~g~ setting (0.26--0.32) led to less contribution of EHC.

For some time it has been known that the urinary CP‐I/(CP‐I + CP‐III) ratio is associated with ABCC2 mutations and it has been suggested that the ratio can serve as a MRP2 trait measure.[27](#psp412348-bib-0027){ref-type="ref"} The increase in CP‐I/(CP‐I + CP‐III) ratio associated with Dubin--Johnson syndrome[28](#psp412348-bib-0028){ref-type="ref"}, [29](#psp412348-bib-0029){ref-type="ref"} might result from increased plasma concentration and urinary excretion of CP‐I due to the diminished MRP2‐mediated biliary excretion of CP‐I. Although MRP2 is also expressed on human kidney proximal tubule epithelia,[30](#psp412348-bib-0030){ref-type="ref"} inhibition of renal MRP2 was not incorporated in our PBPK model because the renal clearance of CP‐I is not affected by RIF.[12](#psp412348-bib-0012){ref-type="ref"}

Yoshida *et al*.[31](#psp412348-bib-0031){ref-type="ref"} summarized the effects of Rotor Syndrome (RS) on the urinary excretion of CP‐I from six previous articles. It was concluded that the ratio of urinary excretion in healthy control (non‐RS) subjects vs. patients with RS (non‐RS/RS) was comparable across the various studies, ranging from 5--20% with the geometric mean of 9.8%. We simulated CP‐I blood concentrations in RS subjects using our PBPK model, assuming that (i) PS~act,inf~ mediated by OATP1B1 and OATP1B3 is decreased to zero and (ii) *v* ~syn~ is unchanged in RS (**Supplementary Text** [S1](#psp412348-sup-0008){ref-type="supplementary-material"}). The resultant simulated steady‐state CP‐I blood concentration for RS subjects was approximately sevenfold higher than that reported for reference (non‐RS) subjects (3.2 nM vs. 0.46 nM, as shown in **Table** [S1](#psp412348-sup-0006){ref-type="supplementary-material"} **B**). Assuming that renal clearance is unchanged in patients with RS, the ratio of urinary excretion (non‐RS/RS) should be 14%, which is within the range that has been reported.

We predicted the blood concentration‐time profiles of four statins in the presence of RIF (**Figure** [3](#psp412348-fig-0003){ref-type="fig"} **a--d**), using substrate‐dependent *K* ~i,u,OATP1Bs~ values (**Table** [S1](#psp412348-sup-0006){ref-type="supplementary-material"} **D**) calculated by multiplying the *K* ~i,u,OATP1Bs~ for CP‐I (**Table** [2](#psp412348-tbl-0002){ref-type="table"}) by the ratio of *in vitro K* ~i,u~ for each statin to CP‐I (**Table** [S2](#psp412348-sup-0007){ref-type="supplementary-material"}). The prediction accuracy (AFE) in the blood concentrations of statins in our clinical data[13](#psp412348-bib-0013){ref-type="ref"} was within 2, except for one case (600 mg RIF with rosuvastatin). In addition, the predicted AUC and C~max~ of statins was well‐correlated with the observed AUC and C~max~ (**Figure** [3](#psp412348-fig-0003){ref-type="fig"} **e,f**). Furthermore, the AFE for predicted and observed AUC ratio is 1.20, and that for C~max~ ratio is 1.36 (**Figure** [S5](#psp412348-sup-0005){ref-type="supplementary-material"} **g,h**). The differences between predicted and observed AUC ratios for pitavastatin and fluvastatin were larger than those for other compounds (overestimation). This might be caused by nonobserved dose‐dependence of RIF on the pharmacokinetics pitavastatin and fluvastatin in the clinical study by Takehara *et al*.[13](#psp412348-bib-0013){ref-type="ref"} For rosuvastatin and atorvastatin, the differences between the predicted and observed C~max~ ratio were large (underestimation). The considerable reason for this is that RIF might affect the absorption process of these compounds by unknown mechanisms (e.g., increase in *k* ~a~ by intestinal efflux transporters, such as breast cancer resistance protein, MRP2, and P‐glycoprotein). Overall, the results of the present study support the predictive performance of our method for practical use in drug development.

Barnett *et al*.[20](#psp412348-bib-0020){ref-type="ref"} estimated *in vivo K* ~i,u~ for the RIF‐mediated inhibition of hepatic elimination clearance using empirical models for CP‐I and rosuvastatin. They showed the difference of *in vivo* RIF *K* ~i,u~ for the hepatic elimination of CP‐I (0.13 μM) and rosuvastatin (0.25 μM). Yoshida *et al*.[31](#psp412348-bib-0031){ref-type="ref"} have also adopted an empirical model for CP‐I. After estimating an *in vivo* RIF *K* ~i,u~ for the hepatic elimination (0.02 μM), the clinical DDI between pravastatin and RIF was well predicted. Thus, *in vivo K* ~i,u~ values estimated in these empirical models were sufficient for explanation of RIF‐mediated change in the blood concentration‐time profile of CP‐I. However, we should keep in mind that the obtained *in vivo K* ~i,u~ value is much lower compared with *in vitro K* ~i,u~ and IC~50~ values for CP‐I (0.18 and 0.78 μM in **Table** [S2](#psp412348-sup-0007){ref-type="supplementary-material"}; 0.25 and 3.3 μM from the previous reports[32](#psp412348-bib-0032){ref-type="ref"}, [33](#psp412348-bib-0033){ref-type="ref"}) and those for statins as other OATP1B substrates (0.30--2.8 μM in **Table** [S2](#psp412348-sup-0007){ref-type="supplementary-material"}; 0.30--5.7 μM in the Drug Interaction Database). *In vivo K* ~i,u~ values estimated using the empirical models should not be applied to other probes directly, because (i) the hepatic clearance used in the empirical models is a hybrid parameter containing the hepatic blood flow and intrinsic clearances (uptake, basolateral efflux, metabolism, and biliary excretion) for CP‐I. By not considering the site of inhibition by RIF, one could greatly impact the estimation of *in vivo K* ~i,u~; and (ii) the former studies did not consider the site of biosynthesis for CP‐I. Actually, the liver is the major organ responsible for the biosynthesis of CP‐I (see [METHODS](#psp412348-sec-0007){ref-type="sec"}). Therefore, hepatic MRP2 function as well as OATP1Bs should be important determinants for CP‐I blood concentration. This should also affect the estimation of *in vivo K* ~i,u~.

Thus, our PBPK modeling approach for CP‐I has the advantage and advancement from the previous empirical modeling approach in terms of consideration of the site of biosynthesis, rate‐determining process in the hepatic elimination, and the inhibition mechanisms, which enables the prediction of complex DDI involving a new chemical entity (NCE) via hepatic transport processes (OATP1Bs and MRP2) based on *in vitro* information, including substrate‐dependent *K* ~i~, as we propose a workflow in **Figure** [4](#psp412348-fig-0004){ref-type="fig"}. (I) Concentration‐time profiles of given NCE obtained in an exploratory, first‐in‐human study (phase‐0) or in a phase‐1 study (dose escalation study) would provide an opportunity to construct a PBPK model, in which several parameters determined *in vitro* and *in silico* are incorporated according to our previous standardized method.[18](#psp412348-bib-0018){ref-type="ref"} Using the NCE\'s PBPK model and our PBPK model for CP‐I, *in vivo K* ~i,OATP1Bs~ for CP‐I can be obtained by analyzing its concentration‐time profiles in the absence and presence of the NCE. (II) *In vitro K* ~i,OATP1B~ values for CP‐I and for probe substrate drugs (e.g., statins) would be needed to calculate *in vivo K* ~i,OATP1Bs~ for the drugs according to the equation shown in **Figure** [4](#psp412348-fig-0004){ref-type="fig"}. (III) Finally, using the calculated *in vivo K* ~i,OATP1Bs~ for the probe substrate drugs, PBPK modeling and simulation would support the prediction of changes in substrate concentration‐time profiles, AUC, and C~max~ caused by the NCE. Although some problems ascribed to experimental techniques *in vitro* remain to be solved (i.e., difficulty in obtaining reliable *in vitro K* ~i,u~ of highly lipophilic compounds due to nonspecific binding), translation of the effect of an NCE on CP‐I pharmacokinetics to effects on clinically used drugs is gradually becoming more accepted.[5](#psp412348-bib-0005){ref-type="ref"}, [7](#psp412348-bib-0007){ref-type="ref"}, [12](#psp412348-bib-0012){ref-type="ref"}, [20](#psp412348-bib-0020){ref-type="ref"}, [34](#psp412348-bib-0034){ref-type="ref"}

![Scheme of the workflow for predicting drug‐drug interactions using coproporphyrin (CP)‐I as an endogenous biomarker. (I) Concentration‐time profiles of a new chemical entity (NCE) obtained in an exploratory, first‐in‐human study (phase‐0) or in a phase‐1 study (dose escalation study) will provide an opportunity to construct its physiologically based pharmacokinetic (PBPK) model, in which several parameters determined *in vitro* and *in silico* are incorporated according to our previous standardized method.[18](#psp412348-bib-0018){ref-type="ref"} Using PBPK models for the NCE and CP‐I, *in vivo K* ~i,OATP1Bs~ for CP‐I can be obtained by analyzing its concentration‐time profiles in the absence and presence of the NCE. (II) *In vitro K* ~i,OATP1Bs~ values for CP‐I and for probe substrate drugs (e.g., statins) will be needed to calculate *in vivo K* ~i,OATP1Bs~ for the drugs. (III) Using the calculated *in vivo K* ~i,OATP1Bs~ for the probe substrate drugs, PBPK modeling and simulation will enable us to predict changes in their concentration‐time profiles, area under the plasma concentration‐time curve (AUC) and peak plasma concentration (C~max~) caused by the NCE.](PSP4-7-739-g004){#psp412348-fig-0004}

In conclusion, the PBPK modeling approach presented herein provides a deeper understanding of the mechanisms governing CP‐I pharmacokinetics and enables complex analyses of the dose‐dependent inhibitory effects of RIF on the hepatic OATP1Bs/MRP2‐mediated transport of CP‐I. Based on the *in vivo K* ~i~ for CP‐I optimized by PBPK modeling, and the ratio of *in vitro K* ~i~ for each statin to CP‐I, we showed that it is possible to accurately predict the blood concentration‐time profiles of OATP1B probe drugs affected by RIF at two dose levels. Presently, the vision is to expand the use the model to include additional OATP1Bs inhibitors beyond RIF.
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**Figure S1**. Uptake and efflux profiles of CP‐I in plated human hepatocytes.
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**Figure S2**. Saturation of CP‐I uptake by OATP1B1, and inhibitory effects of RIF on OATP1B1‐mediated and OATP1B3‐mediated uptakes of CP‐I and statins *in vitro*.
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**Figure S3**. Sensitivity analyses of model parameters to examine effects on the blood concentration‐time profiles of CP‐I in the absence and presence of RIF using the PBPK model incorporating the inhibitions of OATP1Bs and MRP2.
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**Figure S4.** Simulation of blood concentration--time profiles of CP‐I in the absence and presence of RIF using parameters optimized as shown in **Figure** [2](#psp412348-fig-0002){ref-type="fig"} and the PBPK model incorporating the inhibition of OATP1Bs alone.
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**Figure S5.** Prediction of the effect of RIF on blood concentration--time profiles of statins using their PBPK models and parameters including substrate‐dependent *K* ~i,u,OATP1Bs~ (without correction of the in vivo *K* ~i~ based on differences of in vitro *K* ~i~).
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**Table S1.** Parameters used in the PBPK model for CP‐I and statins.
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**Table S2.** IC~50~ values by RIF determined from the uptake experiments using OATP1B1‐ and OATP1B3‐expressing HEK293 cells, and calculated *K* ~i~ values.
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**Supplementary Text S1**. Legends for the supplementary figures. Simulation design. PBPK model structure, parameters and equations. Material and methods for in vitro experiments.
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